Intellia Therapeutics is trading 6.8% down today at $12.05 after Wolfe Research downgraded the company to Underperform from Peerperform. - The firm also set a new price target of $9.00 for the stock, citing valuation concerns. - This downgrade follows recent positive clinical trial updates, but concerns about profitability and competition remain.